C. Beach

发表

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.

R. Greil, H. Döhner, M. Minden, 2015, Blood.

Impact of Lenalidomide Treatment on Overall Survival in Patients With Lower-Risk, Transfusion-Dependent Myelodysplastic Syndromes.

P. Fenaux, A. Giagounidis, U. Platzbecker, 2022, Clinical lymphoma, myeloma & leukemia.

Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes

P. Vyas, B. Skikne, G. Garcia-Manero, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Achievement of red blood cell transfusion independence in red blood cell transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes correlates with serum erythropoietin levels

B. Skikne, P. Fenaux, A. Giagounidis, 2020, Leukemia & lymphoma.

CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia.

B. Skikne, S. Kambhampati, G. Garcia-Manero, 2018, Leukemia research.

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.

H. Döhner, H. Dombret, B. Skikne, 2020, The New England journal of medicine.

Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens

H. Döhner, M. Minden, H. Dombret, 2017, BMC Cancer.

Challenges of phase III trial design for novel treatments in diseases with no standard treatment: the AZA-001 myelodysplasia study model.

E. Estey, L. Silverman, G. Mufti, 2014, Leukemia research.

Incidence rates of treatment-emergent adverse events and related hospitalization are reduced with azacitidine compared with conventional care regimens in older patients with acute myeloid leukemia

H. Döhner, M. Minden, H. Dombret, 2017, Leukemia & lymphoma.

Bioavailability of Azacitidine Subcutaneous Versus Intravenous in Patients With the Myelodysplastic Syndromes

G. Marcucci, M. Eller, L. Silverman, 2005, Journal of clinical pharmacology.

Use of IL-2 and Lymphocytes Following Bone Marrow Transplantation

John A Thompson, M. Benyunes, A. Fefer, 1992 .

Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher‐risk myelodysplastic syndromes

Tsai-Yun Chen, W. Chou, S. Yeh, 2017, Asia-Pacific journal of clinical oncology.

Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.

J. Hainsworth, T. Cosgriff, A. Cohn, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study.

J. Byrd, G. Mufti, J. Bennett, 2007 .

Results of the Initial Treatment Phase of a Study of Three Alternative Dosing Schedules of Azacitidine (Vidaza®) in Patients with Myelodysplastic Syndromes (MDS).

T. Cosgriff, R. Lyons, I. Fernando, 2007 .

The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS)

G. Mufti, P. Fenaux, E. Hellström-Lindberg, 2008 .

Patient outcome measures during prolonged survival in patients (Pts) with high-risk myelodysplastic syndromes (MDS) treated with azacitidine (AZA)

G. Mufti, P. Fenaux, E. Hellström-Lindberg, 2008 .

Azacitidine Prolongs Overall Survival (OS) and Reduces Infections and Hospitalizations in Patients (Pts) with WHO-Defined Acute Myeloid Leukemia (AML) Compared with Conventional Care Regimens (CCR)

L. Silverman, G. Mufti, P. Fenaux, 2008 .

Oral azacitidine prolongs survival of patients with AML in remission independent of measurable residual disease status.

H. Döhner, F. Thol, H. Dombret, 2022, Blood.

A 10 Day Schedule of Azacitidine Induces More Complete Cytogenetic Remissions Than the Standard Schedule In Myelodysplasia and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the E1905 US Leukemia Intergroup Study

J. Gabrilove, P. Greenberg, M. Tallman, 2010 .

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML

M. Tormo, M. Voso, J. Cavenagh, 2021, Blood advances.

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

H. Döhner, H. Dombret, B. Skikne, 2019 .

Overall Survival in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with >30% Bone Marrow Blasts Treated with Azacitidine By Cytogenetic Risk Status: Results of the AZA-AML-001 Study

H. Döhner, M. Minden, H. Dombret, 2014 .

The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update

S. Gore, P. Fenaux, E. Hellström-Lindberg, 2008, Ecancermedicalscience.

124 AZACITIDINE VERSUS CONVENTIONAL CARE REGIMENS (CCR) IN OLDER PATIENTS WITH NEWLY DIAGNOSED AML (>30% MARROW BLASTS) WITH MYELODYSPLASIA-RELATED CHANGES: SUBGROUP ANALYSIS OF THE AZA-AML-001 STUDY

H. Döhner, M. Minden, H. Dombret, 2015 .

Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (>30% Bone Marrow Blasts) with Morphologic Dysplastic Changes: A Subgroup Analysis of the AZA-AML-001 Trial

H. Döhner, M. Minden, H. Dombret, 2014 .

Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care

L. Bullinger, H. Döhner, P. Vyas, 2018, Leukemia.

Response Rates Using International Working Group (IWG) Criteria in Patients with Myelodysplastic Syndromes (MDS) Treated with Azacitidine.

R. Larson, B. Peterson, L. Silverman, 2005 .

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Valeria Santini, Robert Schoch, Pierre Fenaux, 2009, The Lancet. Oncology.

Hematologic Improvement, Transfusion Independence, and Safety Assessed Using Three Alternative Dosing Schedules of Azacitidine in Patients with Myelodysplastic Syndromes.

T. Cosgriff, R. Lyons, J. Backstrom, 2006 .

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

R. Larson, B. Peterson, J. Holland, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic Impact of NPM1 and FLT3 Mutations at Diagnosis and Presence of Measurable Residual Disease (MRD) after Intensive Chemotherapy (IC) for Patients with Acute Myeloid Leukemia (AML) in Remission: Outcomes from the QUAZAR AML-001 Trial of Oral Azacitidine (Oral-AZA) Maintenance

H. Döhner, F. Thol, H. Dombret, 2021, Blood.

Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group

L. Pleyer, R. Greil, H. Döhner, 2017, International journal of molecular sciences.

Efficacy, safety and pharmacokinetics of subcutaneous azacitidine in Chinese patients with higher risk myelodysplastic syndromes: Results from a multicenter, single‐arm, open‐label phase 2 study

Zhi-xiang Shen, Jie Jin, A. Sun, 2018, Asia-Pacific journal of clinical oncology.

Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies.

H. Döhner, B. Skikne, G. Garcia-Manero, 2021, Clinical lymphoma, myeloma & leukemia.

Long‐term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo‐controlled, phase 3 QUAZAR AML‐001 trial

H. Döhner, H. Dombret, B. Skikne, 2023, American journal of hematology.

Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase III, placebo-controlled QUAZAR AML-001 trial

H. Döhner, H. Dombret, B. Skikne, 2021, Haematologica.

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.

H. Döhner, F. Thol, H. Dombret, 2022, Blood.

Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial

H. Döhner, T. Chevassut, H. Dombret, 2021, Journal of Hematology & Oncology.

CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial

H. Döhner, F. Thol, H. Dombret, 2020 .

CC-486 Improves Overall Survival (OS) and Relapse-Free Survival (RFS) for Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC), Regardless of Amount of Consolidation Received: Results from the Phase III QUAZAR AML-001 Maintenance Trial

H. Döhner, H. Dombret, B. Skikne, 2020 .

CC-486 Reduces Hospitalization and Associated Estimated Costs in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy: Results from the QUAZAR AML-001 Maintenance Trial

B. Skikne, S. Kambhampati, A. Oriol, 2020 .

Long-Term Overall Survival (OS) with Oral Azacitidine (Oral-AZA) in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Updated Results from the Phase 3 QUAZAR AML-001 Trial

H. Döhner, H. Dombret, B. Skikne, 2021, Blood.

Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Maintenance Trial

T. Chevassut, H. Dombret, B. Skikne, 2020 .

Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML‐001 trial

B. Skikne, A. Risueño, T. Prebet, 2023, British journal of haematology.

Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens

H. Döhner, M. Minden, H. Dombret, 2017, BMC Cancer.

Randomized study of continuous high-dose lenalidomide , sequential azacitidine and lenalidomide or azacitidine in persons > /-65 years with newly-diagnosed acute myeloid leukemia

R. Vij, S. Kambhampati, R. Gale, 2017 .

Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies

M. Czuczman, V. Komashko, S. Zhou, 2019, Clinical Pharmacokinetics.

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes

M. Tormo, M. Voso, J. Cavenagh, 2021, Blood advances.

Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia

R. Vij, S. Kambhampati, R. Gale, 2017, Haematologica.